Gregory A. Lizée

University of Texas M.D. Anderson Cancer Center

Dr. Lizee earned his Ph.D. degree in 2000 from the University of British Columbia (Vancouver, Canada) studying the role of the MHC class I cytoplasmic domain in antigen cross-presentation and the generation of antiviral immune responses. He performed his postdoctoral studies at the Surgery Branch, National Institutes of Health (Bethesda, Maryland) where he gained valuable experience in human tumor immunology with a clinical and translational focus. He has worked as faculty at M.D. Anderson Cancer Center since 2005, and currently holds cross-appointments as Professor in the Departments of Immunology and Melanoma Medical Oncology. Dr. Lizee’s research over the past 5 years has focused on combining next generation genetic sequencing, mass spectrometry-based proteomics, and wet-bench immunology techniques to identify both shared and personalized tumor antigens. These efforts have led to the development of novel antigen-specific immunotherapies including T cell receptor (TCR)-based therapies and neoantigen peptide vaccines for melanoma, colorectal, pancreatic, and lung cancer patients.